Nelson Delia J, Clark Briony, Munyard Kylie, Williams Vincent, Groth David, Gill Jespal, Preston Henry, Chan Arlene
School of Biomedical Sciences, Curtin University, Bentley, Perth, WA, Australia; CHIRI Biosciences, Curtin University, Perth, WA, Australia.
School of Biomedical Sciences, Curtin University , Bentley, Perth, WA, Australia.
Oncoimmunology. 2017 Jan 19;6(3):e1282590. doi: 10.1080/2162402X.2017.1282590. eCollection 2017.
Historically, the immune environment was not considered an important target for breast cancer treatment. However, the association of lymphocytic infiltrates in triple negative and HER-2 over-amplified breast cancer subtypes with better outcomes, has provoked interest in evaluating the role of the immune system in the luminal B subtype that accounts for 39% of breast cancers and has a poor patient prognosis. It is unknown which immunosuppressive cell types or molecules (e.g., checkpoint molecules) are relevant, or where measurement is most informative. We hypothesize that a profound immunosuppressive tumor and/or lymph node milieu is prognostic and impacts on responses to therapies.
从历史上看，免疫环境并不被认为是乳腺癌治疗的重要靶点。然而，三阴性和HER-2过表达乳腺癌亚型中的淋巴细胞浸润与较好的预后相关，这引发了人们对评估免疫系统在占乳腺癌39%且患者预后较差的管腔B亚型中的作用的兴趣。目前尚不清楚哪些免疫抑制细胞类型或分子（如检查点分子）是相关的，也不清楚在哪里进行测量最具信息量。我们假设，一种深度免疫抑制的肿瘤和/或淋巴结微环境具有预后意义，并会影响对治疗的反应。
